AV-101-002 IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)

NCT05036135

IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients with Pulmonary Arterial Hypertension (PAH)

Associated Conditions

Pulmonary Hypertension

Principal Investigator

Sponsor

Aerovate Therapeutics

The purpose of this study is to evaluate what effects, good or bad, the investigational drug AV-101, comparedt to placebo, has on people with pulmonary arterial hypertension (PAH). In order to measure success for this study it is critical that as many subjects as possible are followed for the duration of the study.

This study is currently enrolling.